Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection.

Leigh Brown AJ, Frost SD, Good B, Daar ES, Simon V, Markowitz M, Collier AC, Connick E, Conway B, Margolick JB, Routy JP, Corbeil J, Hellmann NS, Richman DD, Little SJ.

J Virol. 2004 Mar;78(5):2242-6.

2.

Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.

Martinez-Picado J, Wrin T, Frost SD, Clotet B, Ruiz L, Brown AJ, Petropoulos CJ, Parkin NT.

J Virol. 2005 May;79(10):5907-13.

3.
4.

Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.

Vergne L, Stuyver L, Van Houtte M, Butel C, Delaporte E, Peeters M.

J Clin Virol. 2006 May;36(1):43-9. Epub 2006 Mar 24.

PMID:
16563858
5.

Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation.

Zimmer JM, Roman F, Lambert C, Jonckheer A, Vazquez A, Plesséria JM, Servais JY, Covens K, Weber J, Van Laethem K, Schmit JC, Vandamme AM, Quinones-Mateu ME, De Maeyer M.

J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):255-62. doi: 10.1097/QAI.0b013e318174dca6.

PMID:
18545158
6.

Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006.

Lalezari JP, Ward DJ, Tomkins SA, Garges HP.

J Antimicrob Chemother. 2007 Jul;60(1):170-4. Epub 2007 May 8.

PMID:
17491001
8.

The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication.

Margerison ES, Maguire M, Pillay D, Cane P, Elston RC.

J Antimicrob Chemother. 2008 Apr;61(4):786-91. doi: 10.1093/jac/dkm545. Epub 2008 Feb 4.

PMID:
18252693
9.

Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.

Václavíková J, Weber J, Machala L, Reinis M, Linka M, Brůcková M, Vandasová J, Stanková M, Konvalinka J.

Acta Virol. 2005;49(1):29-36.

PMID:
15929396
10.

Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.

Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA.

AIDS. 1999 Dec 3;13(17):2349-59.

PMID:
10597776
11.

Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.

Song W, Maeda Y, Tenpaku A, Harada S, Yusa K.

Antiviral Res. 2004 Mar;61(3):173-80.

PMID:
15168798
12.

Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.

Vergani B, Cicero ML, Vigano' O, Sirianni F, Ferramosca S, Vitiello P, Di Vincenzo P, Pia De Pasquale M, Galli M, Rusconi S.

J Clin Virol. 2008 Feb;41(2):154-9. Epub 2007 Nov 19.

13.

The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

Maillard A, Chapplain JM, Tribut O, Bentué-Ferrer D, Tattevin P, Arvieux C, Michelet C, Ruffault A.

J Clin Virol. 2007 Feb;38(2):131-8. Epub 2007 Jan 4.

PMID:
17208042
14.

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.

Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, Van PN, Chauvin JP.

AIDS. 2008 Jan 30;22(3):385-93. doi: 10.1097/QAD.0b013e3282f3f16d.

PMID:
18195565
15.

Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.

Loutfy MR, Raboud JM, Walmsley SL, Saskin R, Montaner JS, Hogg RS, Thompson CA, Harrigan PR.

Antivir Ther. 2004 Aug;9(4):595-602.

PMID:
15456091
16.

Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.

Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, Richards N, Hanlon MH, Porter DJ, Wrin T, Parkin N, Tisdale M, Furfine E, Petropoulos C, Snowden BW, Kleim JP.

J Virol. 2002 Aug;76(15):7398-406.

17.

Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.

Kozal MJ, Hullsiek KH, Leduc R, Novak RM, MacArthur RD, Lawrence J, Baxter JD; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

Antivir Ther. 2006;11(4):457-63.

PMID:
16856619
18.

Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.

Doualla-Bell F, Avalos A, Gaolathe T, Mine M, Gaseitsiwe S, Ndwapi N, Novitsky VA, Brenner B, Oliveira M, Moisi D, Moffat H, Thior I, Essex M, Wainberg MA.

Antimicrob Agents Chemother. 2006 Jun;50(6):2210-3.

19.

Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication.

Matsuoka-Aizawa S, Sato H, Hachiya A, Tsuchiya K, Takebe Y, Gatanaga H, Kimura S, Oka S.

J Virol. 2003 Jan;77(1):318-27.

20.

Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment.

Kagan RM, Cheung PK, Huard TK, Lewinski MA.

Antiviral Res. 2006 Aug;71(1):42-52. Epub 2006 Mar 23.

PMID:
16600392

Supplemental Content

Support Center